Rafael Pinheiro

Rafael Pinheiro


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2021 in Nutrition Research Reviews
Verified
Journal Article
Closed access
PDF file
Kamila Sabino BatistaKamila Sabino Batista
Kamila Sabino Batista
JAJuliana Gondim de Albuquerque
Juliana Gondim de Albuquerque
MVMaria Helena Araújo de Vasconcelos
Maria Helena Araújo de Vasconcelos
MBMaria Luiza Rolim Bezerra
Maria Luiza Rolim Bezerra
MBMariany Bernardino da Silva Barbalho
Mariany Bernardino da Silva Barbalho
JAJailane Aquino
Jailane Aquino
Scientists are working to identify prevention/treatment methods and clinical outcomes of coronavirus disease 2019 (COVID-19). Nutritional status and diet have a major impact on the COVID-19 disease process, mainly because of the bidirectional interaction between gut microbiota and lung, that is, the gut–lung axis. Individuals with inadequate nutritional status have a pre-existing imbalance in the gut microbiota and immunity as seen in obesity, diabetes, hypertension and other chronic diseases. Communication between the gut microbiota and lungs or other organs and systems may trigger worse clinical outcomes in viral respiratory infections. Thus, this review addresses new insights into the use of probiotics and prebiotics as a preventive nutritional strategy in managing respiratory infections such as COVID-19 and highlighting their anti-inflammatory effects against the main signs and symptoms associated with COVID-19. Literature search was performed through PubMed, Cochrane Library, Scopus and Web of Science databases; relevant clinical articles were included. Significant randomised clinical trials suggest that specific probiotics and/or prebiotics reduce diarrhoea, abdominal pain, vomiting, headache, cough, sore throat, fever, and viral infection complications such as acute respiratory distress syndrome. These beneficial effects are linked with modulation of the microbiota, products of microbial metabolism with antiviral activity, and immune-regulatory properties of specific probiotics and prebiotics through Treg cell production and function. There is a need to conduct clinical and pre-clinical trials to assess the combined effect of consuming these components and undergoing current therapies for COVID-19.

2 October 2022 in Foods
Verified
Journal Article
Open access
PDF file
TLTatiana Luiza Lucena
Tatiana Luiza Lucena
Kamila Sabino BatistaKamila Sabino Batista
Kamila Sabino Batista
RPRafael Pinheiro
Rafael Pinheiro
HCHassler Cavalcante
Hassler Cavalcante
JGJéssyca Alencar de Sousa Gomes
Jéssyca Alencar de Sousa Gomes
JAJailane Aquino
Jailane Aquino
The aim of this study was to evaluate the effects of supplementing yellow mombin (YM) on the oxidative, somatic, and lipid parameters in rats fed a high-fat diet. A total of 24 adult Wistar rats were randomized into three groups: normal-fat diet (NF), high-fat diet (HF), and high-fat diet with YM supplementation (HFYM). Diets were administered for four weeks, and YM (400 mg/kg) was supplemented via gavage in the last two weeks of the experiment. After the four-week period, the somatic, serum biochemical, and liver oxidative parameters were evaluated. YM has a high antioxidant activity and significant amounts of phenolic compounds, carotenoids, vitamin C, dietary fibre, and minerals. The HFYM group had the lowest body weight (18.75%), body mass index (17.74%), and adiposity (31.63%) compared with the HF group. YM supplementation reduced low-density lipoprotein by 43.05% and increased high-density lipoprotein by 25.73%, but did not improve the triglyceride levels in the serum. YM treatment improved glucose tolerance and lipid peroxidation, and also enhanced the antioxidant capacity, superoxide dismutase, and glutathione peroxidase activities in the liver. These results indicate the lipid-lowering property and potential antioxidant activity of YM against liver oxidative damage caused by a high-fat diet intake, which may be associated with the bioactive compounds present in this fruit.
1

18 May 2023 in Food & Function
Verified
Journal Article
Closed access
PDF file
MVMaria Helena Araújo de Vasconcelos
Maria Helena Araújo de Vasconcelos
RTRenata Leite Tavares
Renata Leite Tavares
MDMaria Letícia da Veiga Dutra
Maria Letícia da Veiga Dutra
Kamila Sabino BatistaKamila Sabino Batista
Kamila Sabino Batista
ADAline Barbosa D'OLiveira
Aline Barbosa D'OLiveira
JAJailane Aquino
Jailane Aquino
The present study aimed to evaluate the effect of E-VCO on the neurobehaviour and intestinal health parameters of obesity-induced rats, focusing on food consumption, body composition, bacterial and faecal organic acids and histological analyses in the hippocampus and colon. A total of 32 male Wistar rats were randomized into healthy (HG, n = 16) and obese groups (OG, n = 16), which consumed a control or cafeteria diet for eight weeks, respectively. After this period, they were subdivided into four groups: healthy (HG, n = 8); healthy treated with E-VCO (HGCO, n = 8); obese (OG, n = 8); obese treated with E-VCO (OGCO, n = 8), continuing for another eight weeks with their respective diets. The treated groups received 3000 mg kg−1 of E-VCO and control groups received water via gavage. Food preference, body weight gain, body composition, anxiety- and depression-like behaviour were evaluated. Bacteria and organic acids were evaluated in faeces, and histological analyses of the hippocampus and M1 and M2 macrophages in the colon were performed. E-VCO reduced energy intake (16.68%) and body weight gain (16%), although it did not reduce the fat mass of obese rats. E-VCO showed an antidepressant effect, increased lactic acid bacteria counts and modulated organic acids in obese rats. Furthermore, E-VCO protected the hippocampus from neuronal degeneration caused by the obesogenic diet, decreased the M1 macrophage and increased the M2 macrophage population in the gut. The results suggest neurobehavioural modulation and improved gut health by E-VCO, with promising effects against obesity-related comorbidities.